AlphaHelix Molecular Diagnostics AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 5.52 million compared to SEK 6.67 million a year ago. Revenue was SEK 5.63 million compared to SEK 6.96 million a year ago. Net loss was SEK 1.19 million compared to SEK 0.107 million a year ago. Basic loss per share from continuing operations was SEK 0.02.
For the nine months, sales was SEK 24.37 million compared to SEK 31.91 million a year ago. Revenue was SEK 24.65 million compared to SEK 32.55 million a year ago. Net loss was SEK 2.19 million compared to net income of SEK 5.04 million a year ago. Basic loss per share from continuing operations was SEK 0.03 compared to basic earnings per share from continuing operations of SEK 0.08 a year ago.